Alteogen has publicly identified Sanofi as its first licensing partner for its ALT-B4 technology, which was part of a licensing agreement signed in 2019.
On June 18, Alteogen announced that the initial licensing agreement for the subcutaneous formulation technology based on its Hybrozyme platform was with Sanofi. The details of the agreement had previously been kept confidential.
In November 2019, Alteogen disclosed that it had entered into a non-exclusive licensing agreement worth $1.373 billion with a global top 10 pharmaceutical company.
ALT-B4 is a recombinant human hyaluronidase technology that enables the conversion of intravenous medications to a more convenient subcutaneous form. This technology is a key component of Alteogen's Hybrozyme platform.
Following the partnership with Sanofi, Alteogen has expanded its licensing agreements with eight global pharmaceutical companies, including MSD, AstraZeneca, GSK, Daiichi Sankyo, Biogen, Sandoz, and Intas, enhancing its platform's competitiveness.
Alteogen CEO Jeon Tae-yeon stated, "The disclosure of our partner validates the technological capabilities of the ALT-B4 platform once again. We believe it will enhance patient convenience and quality of life across various treatment areas, including oncology and autoimmune diseases."
Meanwhile, there is growing optimism regarding the mitigation of patent risks. On June 8, the U.S. Patent Trial and Appeal Board (PTAB) ruled again to invalidate Halozyme's MDase patent.
This ruling marks the third final decision in the post-grant review (PGR) initiated by Merck, all resulting in patent invalidation. As Halozyme's key MDase patents continue to be invalidated, both Merck and Alteogen appear to be gaining an advantage in the patent dispute.
Additionally, Alteogen's partner Merck is expected to benefit from a compensation payment in a patent lawsuit against Halozyme in the UK, which may positively influence ongoing litigation in the U.S. and other countries.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.